Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab Maintenance in High-Risk Neuroblastoma
NCT06047535Phase 4Not yet recruiting
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 4 trial of naxitamab in neuroblastoma, sponsored by SciClone Pharmaceuticals (Holdings) Limited. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06047535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047535.